Nordion (Canada) Inc., a health science company, provides various products and services for the prevention, diagnosis, and treatment of diseases worldwide. The company operates in two segments: Sterilization technologies and medical isotopes. The Sterilization Technologies segment offers Cobalt-60, a radioactive metal that emits radiation and sterilizes items by destroying contaminating micro-organisms; dosimetry and professional services; as well as designs, constructs, and maintains commercial gamma sterilization systems. The Medical Isotopes segment provides various products that are used in the diagnosis and treatment of diseases, including cardiac and neurological conditions and various types of cancer. It offers Molybdenum-99, which decays into Technetium-99, a diagnostic that is used in nuclear medical procedures; Xenon-133, used in lung scans; Iodine-131, to treat hyperthyroidism, thyroid cancer, and non-Hodgkin’s lymphoma; Iodine-125, to treat prostate cancer; and Yttrium-90, to treat liver cancer and non-Hodgkin’s lymphoma. This segment also provides cyclotron isotopes, such as Iodine-123 to diagnose thyroid disease; Thallium-201 to diagnose and assess risk of coronary artery heart disease; Palladium-103 for treating prostate cancer; Strontium-82 for cardiac imaging; and Indium-111 and Gallium-67 to diagnose cancer, as well as offers radiopharmaceutical and contract manufacturing services. Nordion (Canada) Inc. serves radiopharmaceutical and pharmaceutical manufacturers, biotechnology companies, manufacturers of medical supplies and devices, contract sterilizers, hospitals, and academic and government institutions, as well as the food and consumer goods industries. The company was formerly known as MDS Inc. and changed its name to Nordion (Canada) Inc. in November 2010. Nordion (Canada) Inc. was incorporated in 1946 and is headquartered in Ottawa, Canada with an additional office in Abingdon, United Kingdom. As of August 6, 2014, Nordion (Canada) Inc. operates as a subsidiary of Sotera Health Company.